Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 576482, 7 pages
http://dx.doi.org/10.1155/2014/576482
Research Article

Inter- Not Intraindividual Differences in sTWEAK Levels Predict Functional Deterioration and Mortality in Patients with Dilated Cardiomyopathy

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

Received 24 March 2014; Revised 4 June 2014; Accepted 5 June 2014; Published 24 June 2014

Academic Editor: Yves Denizot

Copyright © 2014 Kai-Uwe Jarr et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. C. Burkly, J. S. Michaelson, and T. S. Zheng, “TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses,” Immunological Reviews, vol. 244, no. 1, pp. 99–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. S. R. Wiley, L. Cassiano, T. Lofton et al., “A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis,” Immunity, vol. 15, no. 5, pp. 837–846, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. L. C. Bover, M. Cardó-Vila, A. Kuniyasu et al., “A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications,” Journal of Immunology, vol. 178, no. 12, pp. 8183–8194, 2007. View at Google Scholar · View at Scopus
  4. J. A. Moreno, T. Dejouvencel, J. Labreuche et al., “Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 6, pp. 1253–1262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Urbonaviciene, J. L. Martin-Ventura, J. S. Lindholt et al., “Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease,” Atherosclerosis, vol. 219, no. 2, pp. 892–899, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Llauradó, J. M. González-Clemente, E. Maymó-Masip, D. Subías, J. Vendrell, and M. R. Chacón, “Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study,” PLoS ONE, vol. 7, Article ID e43919, 2012. View at Publisher · View at Google Scholar
  7. J. M. Valdivielso, B. Coll, J. L. Martín-Ventura et al., “Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease,” Journal of Nephrology, vol. 26, pp. 1105–1113, 2013. View at Google Scholar
  8. O. Kowal-Bielecka, M. Bielecki, S. Guiducci et al., “High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis,” Arthritis Research & Therapy, vol. 15, article R69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Chorianopoulos, K. Jarr, H. Steen, E. Giannitsis, N. Frey, and H. A. Katus, “Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome,” Atherosclerosis, vol. 211, no. 1, pp. 322–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. L. Martín-Ventura, J. S. Lindholt, J. A. Moreno et al., “Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms,” Atherosclerosis, vol. 214, no. 2, pp. 486–489, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. I. Yilmaz, A. Sonmez, A. Ortiz et al., “Soluble TWEAK and PTX3 in nondialysis CKD patients: Impact on endothelial dysfunction and cardiovascular outcomes,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 4, pp. 785–792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Chorianopoulos, M. Rosenberg, C. Zugck, J. Wolf, H. A. Katus, and N. Frey, “Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure,” European Journal of Heart Failure, vol. 11, no. 11, pp. 1050–1056, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Richter, K. Rychli, P. J. Hohensinner et al., “Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure,” Atherosclerosis, vol. 213, no. 2, pp. 545–548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. N. G. Mahon, B. P. Madden, A. L. P. Caforio et al., “Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy,” Journal of the American College of Cardiology, vol. 39, no. 3, pp. 455–462, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. A. L. P. Caforio, P. J. Keeling, E. Zachara et al., “Evidence from family studies for autoimmunity in dilated cardiomyopathy,” Lancet, vol. 344, no. 8925, pp. 773–777, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. A. L. P. Caforio, N. G. Mahon, M. K. Baig et al., “Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives,” Circulation, vol. 115, no. 1, pp. 76–83, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Jain, A. Jakubowski, L. Cui et al., “A novel role for tumor necrosis factor-like weak inducer of apoptosis (tweak) in the development of cardiac dysfunction and failure,” Circulation, vol. 119, no. 15, pp. 2058–2068, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Mustonen, H. Säkkinen, H. Tokola et al., “Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats,” Acta Physiologica, vol. 199, no. 1, pp. 11–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Chorianopoulos, T. Heger, M. Lutz et al., “FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK,” Basic Research in Cardiology, vol. 105, no. 2, pp. 301–313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Moreno, B. Muñoz-García, J. L. Martín-Ventura et al., “The CD163-expressing macrophages recognize and internalize TWEAK. Potential consequences in atherosclerosis,” Atherosclerosis, vol. 207, no. 1, pp. 103–110, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Fick, I. Lang, V. Schäfer et al., “Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14),” Journal of Biological Chemistry, vol. 287, no. 1, pp. 484–495, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Jasiewicz, K. Kowal, O. Kowal-Bielecka et al., “Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension,” Cytokine, vol. 66, pp. 40–45, 2014. View at Google Scholar
  23. D. Bertin, D. Stephan, M. Khrestchatisky, and S. Desplat-Jego, “Is TWEAK a biomarker for autoimmune/chronic inflammatory diseases?” Frontiers in Immunology, vol. 4, article 489, 2013. View at Google Scholar